Erratum: Association between recent herpes zoster but not herpes simplex infection and subsequent risk of malignancy in women: A retrospective cohort study (Epidemiology And Infection (2013) DOI: 10.1017/S0950268813001702);Association between recent herpes zoster but not herpes simplex infection and subsequent risk of malignancy in women: A retrospective cohort study

Epidemiology and Infection

Volumn 142, Issue 5, 2014, Pages 1008-1017

  Buntinx, F ^a,b   Bartholomeeusen, S ^a   Belmans, A ^a   Mathei, C ^a   Opdenakker, G ^c   Sweldens, K ^d   Truyers, C ^a   Van Ranst, M ^e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Dermatology Practice   (Belgium)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Herpes zoster; malignancy; retrospective cohort study; survival analysis

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIMARY MEDICAL CARE; PROSTATE CANCER; RETROSPECTIVE STUDY; ERRATUM; ERROR; AGE DISTRIBUTION; CHILD; HERPES SIMPLEX VIRUS; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; VARICELLA ZOSTER VIRUS; VIRUS IDENTIFICATION;

ADULT; AGED; BELGIUM; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK;

EID: 84897034991     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813002422     Document Type: Erratum

References (29)

1. Arvin A. Aging, immunity, and the varicella-zoster virus. New England Journal of Medicine 2005; 352: 2267-2267
2. Smith JB, Fenske NA. Herpes zoster and internal malignancy. Southern Medical Journal 1995; 88: 1089-1092
3. Buntinx F, et al. Is herpes zoster a marker for occult or subsequent malignancy? British Journal of General Practice 2005; 55: 102-107
4. Fueyo MA, Lookingbill DP. Herpes zoster and occult malignancy. Journal of the American Academy of Dermatology 1984; 11: 480-482
5. Ragozzino MW, et al. Risk of cancer after herpes zoster: A population-based study. New England Journal of Medicine 1982; 307: 393-397
6. Cotton SJ, et al. The risk of a subsequent cancer diagnosis after herpes zoster infection: Primary care database study. British Journal of Cancer 2013; 108: 721-726
7. Hui-Fen C, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: A population-based study. Journal of Epidemiology. doi:10.2188/jea.JE20120155
8. Okkes IM, et al. The March 2002 update of the electronic version of ICPC-2. A step forward to the use of ICD-10 as a nomenclature and a terminology for ICPC-2. Family Practice 2002; 19: 543-546
9. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010. (http://www. whocc.no/atc-ddd-index/). Accessed 18 July 2013
10. Intego. www.intego.be. Accessed 1 April 2013
11. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: Recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report 2008; 57: 1-30
12. Truyers C, et al. Intego in daily practice: Incidence of herpes zoster. Huisarts Nu 2005; 34: 260-262
13. Lousbergh D, et al. Ten years of cancer in the Belgian province of Limburg (1996-2005). Hasselt, LIKAS, 2007
14. Galimberti S, Sasieni P, Valsecchi MG. A weighted Kaplan-Meier estimator for matched data with application to the comparison of chemotherapy and bonemarrow transplant in leukaemia. Statistics in Medicine 2002; 21: 3847-3864
15. Lin DY, Wei LJ. The robust inference for the proportional hazards model. Journal of the American Statistical Association 1989; 84: 1074-1078
16. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557-572
17. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-46
18. SAS Institute Inc. SAS software, version 9.2 of the SAS System for Windows. SAS Institute Inc., Cary, NC, USA: 2002
19. Vankrunkelsven P, et al. Reduction in hormone replacement therapy and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Research and Treatment 2009; 118: 425-432
20. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008; 372: 608-610
21. Wyburn-Mason R. Malignant change arising in tissue affected by herpes. British Medical Journal 1955; 2: 1106-1109
22. Serraino D, et al. Socio-economic indicators, infectious diseases and Hodgkin's disease. International Journal of Cancer 1991; 47: 352-357
23. Tucker WE Jr., et al. Preclinical toxicology studies with acyclovir: Carcinogenicity bioassays and chronic toxicity tests. Fundamental and Applied Toxicology 1983; 3: 579-586
24. Gramenzi A, et al. Medical history and the risk of multiple myeloma. British Journal of Cancer 1991; 63: 769-772
25. La Vecchia C, Negri E, Franceschi S. Medical history and the risk of non-Hodgkin lymphomas. Cancer Epidemiology, Biomarkers and Prevention 1992; 1: 553-556
26. Wolff HH, Wendt V, Winzer M. Cutaneous pseudolymphoma at the site of prior herpes zoster eruption. Archives of Dermatological Research 1987; 279: S52-S54
27. Mishra D, Raji MA. Squamous cell carcinoma occurring at site of prior herpes zoster of the scalp: Case report of Marjolin ulcer. Melanoma Research 2003; 13: 635-639
28. Konjevic G, et al. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. British Journal of Haematology 1999; 104: 144-151
29. Yang CM, et al. Natural killer cell deficiency associated with Hodgkin's lymphoma. Journal of the Formosan Medical Association 2002; 101: 73-75.